In response to today’s decision by the U.S. Patent Trial and Appeal Board (PTAB), the University of California has issued a formal statement, which may be read here.
The board ruled that patents filed by the Broad Institute and the UC group do not contain the same patentable claims, though there is substantial overlap. Therefore, the Broad’s existing patents for applying CRISPR-Cas9 gene editing in eukaryotic cells will stand. The broader UC patent, for use of CRISPR-Cas9 in any cell type, will proceed toward issuance.
A longer press release describes the patent dispute in greater detail, providing background and context for the PTAB decision.
“I am pleased that research using CRISPR-Cas9 continues to drive exciting advances in many areas of biology,” states IGI Executive Director Jennifer Doudna. “I am convinced that this technology will solve important problems in clinical medicine, drug discovery, and agriculture.”